Why We Could Be Wrong Our $420 target sits below current levels, a gap small enough to be erased by a single catalyst. Real upside could come from faster than expected Optimus production at Fremont, where lines are being installed with 1 million robots/year capacity, or from FSD regulatory approval in China. A 27% Monthly Rally Meets an Overbought Tape Tesla has ripped 27.53% over the past month and 49.2% over the past year, though shares are still down 1.05% year to date. The stock sits between a 52-week high of $498.83 and a 52-week low of $273.21. RSI closed at 74.06, firmly overbought. The fundamental backdrop justifies the move. Q1 FY26 delivered EPS of $0.41 versus the $0.3592 estimate, a 14.14% beat, with revenue of $22.39B (+15.78% YoY). Automotive gross margin expanded to 21.1% from 16.2%, FSD subscriptions hit 1.28 million (+51% YoY), and free cash flow surged 117.47% to $1.44B. Tesla launched Unsupervised Robotaxi in Dallas and Houston in April. The Case for $500+ Bulls have real ammunition. Cybercab, Tesla Semi, and Megapack 3 all enter volume production in 2026. Optimus production lines at Fremont target 1 million robots/year capacity. The AI5 chip tape-out completed in April 2026, with production in 2027. If Optimus and Robotaxi monetize on Musk’s timeline, a $500 to $550 price tag is defensible. Cash sits at $44.74B with debt/equity of 0.10, giving Tesla room to invest aggressively. What Could Go Wrong The bear case starts with valuation. A PEG of 5.9 and price-to-sales of 16.44 leave little margin for execution slips. Q4 FY25 deliveries fell 16% YoY to 418,227 units, and inventory now sits at 27 days of supply versus 22 prior year. Regulatory credit revenue erodes, from $739M in Q3 24 to $417M in Q3 25. Operating expenses jumped 37% to 50% YoY on AI R&D. A bear scenario takes shares toward $340. Bulls counter that the opex surge funds Optimus, AI5, and Robotaxi, the exact assets justifying the multiple. Q1 26 margin expansion suggests the investment is converting. Tesla Price Prediction 2026-2030 Our price target is $420, recommendation hold, confidence 62%. The stock is fundamentally healthier than 12 months ago, but the tape is stretched and prediction markets show a 70% probability of a down day on May 12. A constructive re-rating likely requires RSI cooling below 60 and Q2 deliveries clearing 450,000 units, while FSD China approval delays or slipping Optimus production timelines would reinforce the cautious stance. Year